Zura Bio Limited (NASDAQ:ZURA) Receives Average Rating of “Moderate Buy” from Analysts

Zura Bio Limited (NASDAQ:ZURA) has earned a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $10.75.

Several analysts have weighed in on ZURA shares. Wedbush reaffirmed an “outperform” rating and set a $15.00 price objective on shares of Zura Bio in a research note on Wednesday, July 1st. Wall Street Zen cut shares of Zura Bio from a “sell” rating to a “strong sell” rating in a research note on Sunday, July 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a report on Monday, July 6th. Finally, William Blair initiated coverage on Zura Bio in a research report on Wednesday, July 8th. They set an “outperform” rating on the stock.

Institutional Trading of Zura Bio

Large investors have recently made changes to their positions in the business. Suvretta Capital Management LLC raised its holdings in shares of Zura Bio by 1.7% in the fourth quarter. Suvretta Capital Management LLC now owns 5,567,001 shares of the company’s stock valued at $29,171,000 after buying an additional 94,110 shares during the last quarter. VR Adviser LLC grew its holdings in Zura Bio by 15.4% during the 4th quarter. VR Adviser LLC now owns 5,345,115 shares of the company’s stock worth $28,008,000 after acquiring an additional 713,899 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Zura Bio by 78.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock worth $4,893,000 after acquiring an additional 2,052,732 shares during the last quarter. Siren L.L.C. increased its position in Zura Bio by 187.3% in the 1st quarter. Siren L.L.C. now owns 3,734,866 shares of the company’s stock valued at $22,222,000 after acquiring an additional 2,434,866 shares in the last quarter. Finally, Commodore Capital LP acquired a new stake in Zura Bio in the 1st quarter valued at about $19,338,000. Institutional investors own 61.14% of the company’s stock.

Zura Bio Stock Performance

ZURA opened at $5.40 on Thursday. The firm has a market cap of $512.35 million, a price-to-earnings ratio of -4.95 and a beta of -0.03. The firm’s 50-day simple moving average is $4.53 and its 200-day simple moving average is $5.37. Zura Bio has a twelve month low of $1.35 and a twelve month high of $7.44.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.05). As a group, sell-side analysts anticipate that Zura Bio will post -0.76 EPS for the current fiscal year.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.